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Introduction 
F-actin (fibrillar actin) is one of the cytoskeletal pro-
teins which forms microfilaments. Cytoskeletal pro-
teins regulate many crucial cell functions, such as
growth, proliferation, differentiation, movement or
transport [1]. Despite indisputable F-actin occurrence
in the cytoplasm, localization of polymerized form of
actin within the area of nucleus still raises many con-
troversies. G-actin (globular actin), which is the pre-
cursor for F-actin, is present in the nucleus and it's
responsible for transcription factors and RNA poly-
merases regulation. Some data indicate that the pool of
nuclear G-actin is insufficient for polymerization to F-
actin. On the other hand, F-actin was found in
SWI/SNF chromatin remodeling complexes [2,3] and
in Xenopus oocytes, during the meiotic maturity [4].  It
is probable that nuclear actin regulates the activity of
histone acetyltransferase, ATPase present in chromatin
remodeling complexes and that it controls functions of
transcription factors from the myocardin/MAL family,
with filaments polymerization and depolymerization
being directly involved in these processes [4-6].
Arsenic trioxide (As2O3, ATO) is well known
chemical compound and despite its high toxicity, as
early as in fifteenth century it was known that in low
doses it has therapeutic properties [7]. In the begin-
ning, medications based on arsenic trioxide, were
applied mostly superficially, as ointments for skin can-
cers, however in the '70s of twentieth ATO was started
to use in intravenous infusions [8-9].
Nowadays, As2O3 is known to be efficient in the
treatment of acute promyelocytic leukemia and
myelodysplastic syndromes (MDS) [10-11]. It was
also started to be used in cases of acute myeloid
leukemia, multiple myeloma and solid carcinoma [9].
In last years studies over the effect of ATO has mainly
included experiments on cell lines, i.a. glioma,
prostate, ovarian, gallbladder, intestinal and cervical
cancers [12-16]. There are ongoing clinical trials to
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study the application of this compound in the treatment
of circulatory and lymphatic system proliferative dis-
eases. It is used not only in the monotherapy but also
in combination with other compounds, i.a. retinoid
acid, ascorbic acid and GM-CSF [17-19].The impact
of ATO bases mainly on the inhibition of proliferation
and introduction of cancer cells on the route of pro-
grammed cell death. Its apoptotic effect has been
proved for many years, however scientists all over the
world are still proposing its new mechanisms. It is
suggested that arsenic trioxide may be involved in the
effect on the activity of JNK kinases, NFκB transcrip-
tion factor, glutathione, caspases as well as pro- (Bax,
Bak, Bid) and antiapoptotic proteins (Bcl-2, Bcl-XL)
[20-24]. It was demonstrated by Chen et al. [25] that
ATO may have an apoptotic effect, by degradation of
the PML/RARα fusion protein and downregulation of
bcl-2 expression. On the contrary, a suggestion exists
that ATO can modulate the glutathione redox system
and it is independent of PML/RAR? and it does not
require downregulation of bcl-2 expression [8]. The
aim of this work was to study F-actin organization in
whole cells and nuclei isolated from cells undergoing
apoptosis, induced by Trisenox which contains arsenic
trioxide as active substance, and it is used in leukemia
treatment. 
Materials and methods
Cell Culture. Study material was K-562 cell line (human ery-
throleukemic cell line ATCC CCL 243). Cells were grown in RPMI
1640 medium supplemented with 10% (m/v) fetal bovine serum
(FBS) and antibiotics, at 37°C in a 5% CO2 atmosphere. Apoptosis
was induced by Trisenox (Cephalon, UK) – drug used in cases of
acute promyelocytic leukemia, which contains As2O3 (1 mg/ml).
Trisenox is water-soluble form of ATO, which includes additional
factors adjusting pH. There were used ATO doses of 0.6, 1.2 and
2.4 μg/ml of medium. Cells were incubated with the cytostatic for
24 hours. Control cells were grown in the same conditions, with-
out the addition of Trisenox to the medium.
Nuclei isolation. Cellular precipitation was suspended in homoge-
nizing environment of: 0.5 M Tris-HCl (pH 7.5); 1 M saccharose;
0.5 M CaCl2; 0.5 M MgCl2; 2-mercaptoethanol; Nonidet. The
environment-suspension ratio was 5:1. Homogenate was crushed
with Teflon piston in glass homogenizer on ice and than poured to
centrifugal tubes and centrifuged at 700g (10 min, 2°C). Precipita-
tion was suspended in 1ml of homogenizing environment, without
Nonidet and slowly overlaid on present in centrifugal tube cooled
solution of: 0.5 M Tris-HCl (pH 7.5); 1 M saccharose; 0.5 M KCl;
0.5 M MgCl2; glycerol and 2-mercaptoethanol. Mixture was cen-
trifuged at 700g (10 min, 2°C). Supernatant was carefully decant-
ed and precipitation was suspended in 1ml of fixing environment
(4% (v/v) paraformaldehyde in  PBS, pH 7.4).
Fluorescence microscopy. In order to estimate F-actin distribution
at the level of classical fluorescence microscope, cellular or
nuclear precipitations were centrifuged onto glass slides and fixed
with 4% (v/v) paraformaldehyde in  PBS, pH 7.4 (20 min, RT).
Specimens were rinsed in PBS and F-actin was labeled with phal-
loidin conjugated to Alexa Fluor 488 (Molecular Probes, Eugene,
Oregon, USA) for 20 min (methanol stock was diluted 1:40 in
PBS). Nuclei were counterstained with DAPI (4,6-diamidino-2-
phenylindole). Eclipse E800 microscope with Epi-fluorescence
attachment (Nikon, Tokyo, Japan) was used to estimate labeled
specimens. Analysis of fluorescent imaging was done with the use
of NIS-Elements software (Nikon Instruments).
Flow cytometry
Cell cycle analysis. Apoptosis was detected by the terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) technique using the APO-DIRECT kit
(BD Bioscience, Pharmingen) according to the instruction of the
supplier with following modifications in fixation. Cells were fixed
on ice for 15 min with 1% formaldehyde and permeabilized in 70%
ethanol for 30 min on ice. The PI/RNase solution used to detect
stage of cell cycle was added succeeding TUNEL-FITC labeling.
Further analysis was performed on a Becton Dickinson FACScan.
For cell cycle analysis doublets were excepted from the final
analysis using linear plots FL2-A towards, to FL2-W. Cells were
identified as G0/G1, S, G2/M and cells with a DNA content of
more than 4n and less than 2n (apoptotic DNA). By using FlowJo
cell cycle analysis software (Tree Star, USA) were determined the
percentages of cells in G1, S, G2/M cell cycle phases.
Apoptosis. Staining with Annexin V-FITC Apoptosis Detection Kit
(BD Pharmingen, San Diego, CA) was used to determine the apop-
tosis, employed according to manufacturer's instructions. Nuclei
were counterstained with propidium iodide. The supernatant was
removed binding buffer and annexin V FITC were added. The cell
were incubated for 15 min and then centrifuged. Following super-
natant removal, binding buffer and PI (propidium iodie), were added
to the cell. Then, the cells were incubated for 5 min. Further analy-
sis was performed with the use of Becton Dickinson FACScan. 
F-actin content. Cells were fixed with 4% paraformaldehyde (20
min at 4°C) and afterwards rinsed with PBS and permeabilized
with 0.1 % Triton X-100 (3 min). After washing in PBS, Alexa
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Fig. 1. The percentages of apoptotic cells in K-562 cell line after
treatment with ATO. Cells were treated with ATO for 24h at con-
centrations: 0.6, 1.2 and 2.4 µg/ml. Together with increasing of ATO
dose there were observed increase of apoptotic cells percentages.
Fluor 488-phalloidin (Molecular Probes, Eugene, Oregon, USA)
was used to stain the material (20 min, RT). Becton Dickinson
FACScan was used to subsequent analysis. 
Statistical analysis. STATISTICA 6.0 for Windows (StatSoft soft-
ware, Tulsa, OK, USA) was used for the statistical analysis. All
comparisons based on ANOVA Repeated Measures Designs and
were presented as Duncan's test results.
Results
Arsenic trioxide induces apoptosis, even with the low-
est dose. Number of apoptotic K-562 cells increases
together with the dose of used compound. In control
cells the level of apoptosis is minimal and it does not
exceed 2.5%. However the population of apoptotic
cells rises to 24.7% with 0.6 μg/ml, 33% with 1.2
μg/ml and 42% with 2.4 μg/ml dose of ATO used
(Fig.1). Under the influence of ATO F-actin undergoes
reorganization, both in whole cells and in isolated cel-
lular nuclei. In control cells F-actin is localized most-
ly at peripheries, but is also present in cytoplasm, in
the form of network and granulated structures (Fig.
2A). Nuclei does not show apoptotic features (Fig. 2A
DAPI). After the treatment with the lowest arsenic tri-
oxide dose (0.6 μg/ml) the number of cells significant-
ly decreases and F-actin – besides the localization in
cytoplasm – is present mainly at cells peripheries,
where it forms granulates. DAPI staining reveals apop-
totic features within the nucleus (Fig. 2B). The use of
medium dose (1.2 μg/ml) causes rapid decrease in cell
number and F-actin placement at cells peripheries and
the highest dose of 2.4 μg/ml induces evident granula-
tion of F-actin present at cells edges (Fig. 2 C,D). 
Quantitative studies, performed with flow cytome-
ter, show that the level of F-actin in whole cells is
changing after the application of ATO (Fig. 3,4). In
control cells fluorescence intensity is order of 2500,
however after application of the lowest ATO dose in
about 60% of cells population decreasing to value near
200. Remaining 40% of cells is also demonstrating
lower fluorescence level. In dose 1.2 μg/ml is increas-
ing cell number with lower level of F-actin fluores-
cence, however in comparison to the lowest dose (0.6
μg/ml) fluorescence intensity is growing slightly.
Analysis of 2.4 μg/ml dose also display not signifi-
cantly grow of F-actin fluorescence in comparison to
previous dose, but cell number with fluorescence on
very high level achieve only 6%. There were statisti-
cally significant differences (Duncan's test, p<0.05).
Isolated nuclei also show F-actin reorganization
(Fig.5). In comparison to control cells nuclei, where it
is present as a network, mainly at nucleus peripheries,
the lowest dose forces it to form granulates and with
the medium dose used, this granulation is evident.
Nuclei were not isolated during highest ATO dose
treatment, as there was a large percentage of apoptotic
cells, showing their disintegration. Besides studies,
showing the percentage of apoptotic cells, it was also
tested the cell division cycle. Results points out the
increased number of cells in G1 phase and decreased
in G2 phase, after ATO treatment, in comparison to
control (Fig. 6). 
Discussion
The apoptotic effect of arsenic trioxide has been
known for years. This cytostatic is used in the treat-
ment of acute promyelocytic leukemia (Trisenox drug)
and it also induces programmed cell death in non-
leukemic cell lines, i.a. breast, ovarian, prostate and
liver cancers, multiple myeloma, glioma and gallblad-
der [11-16,20,26-29]. Results of present work, are sim-
ilar to those obtained by Wang et al. [30] and Shim et
al. [31]. which show apoptotic effect of ATO on K-562
cell line. During the apoptosis, cytoskeleton undergoes
reorganization. Previous works, with the use of other
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Fig. 2. Alteration in the organization of actin cytoskeleton in K-562 cell line after treatment different arsenic trioxide doses. In control
cells F-actin was localized mostly around the cell periphery. After ATO treatment aggregates of F-actin were formed and localized with-
in the cytoplasm. A – control (F-actin, DAPI); B – 0.6 µg/ml (F-actin, DAPI); C – 1.2 µg/ml (F-actin, DAPI); D – 2.4 µg/ml  (F-actin,
DAPI).
proapoptotic factors points changes in all of these
structure proteins. The aim of present work was to
show arsenic trioxide influence on one of the elements
of cytoskeleton – actin filaments. Results indicate on
F-actin reorganization. In control cells actin filaments
form network in the cytoplasm and they are localized
at cells peripheries, whereas with the addition of cyto-
static they transform into granulated structures also
placed in the peripheries. This effect is getting stronger
together with the increase of ATO dose. Previous stud-
ies, described by Shen et al. also point reorganization
of F-actin structure under influence of ATO, in SHEE
(embryonic esophageal epithelium) cells [32]. They
show changes in F-actin organization, from fibrillar
structures within whole cytoplasm of control cells to
punctual structures in SHEE cells, shrinked after
arsenic trioxide. Similar results of F-actin reorganiza-
tion due to the application of other cytostatics i.a.
taxol, doxorubicin and growth factors (ATRA, G-CSF)
are described [34-35]. F-actin accumulation on cells
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Fig. 3,4. Flow cytometric analysis of F-
actin content in K-562 cell line after ATO
treatment. Cells were treated with ATO
for 24h at concentrations: 0.6, 1.2 and
2.4 µg/ml. Fluorescence intensity analy-
sis of F-actin in K-562 showed changes
of fluorescence intensity.
edges is probably related to its participation in the for-
mation of apoptotic blebs [36]. Those structures are
characteristic for apoptosis and after cell disintegration
they form so-called apoptotic bodies, containing cellu-
lar organelles and remains of chromatin and cyto-
plasm. Many researchers, from all over the world,
point this protein participation in the formation of
apoptotic structures. Keller et al. [37] reveal local
reorganization of F-actin, while the creation of apop-
totic blebs, whereas Cotter et al. [38] point necessary
actin polymerization during the formation of apoptotic
blebs. F-actin rich labeling in places of formation was
observed also after the use of doxorubicin and taxol, in
CHOAA8, HL-60 and K-562 cell lines [36,39].
Described results indicate the indisputable participa-
tion of skeleton structures in apoptosis, despite the
fact, that some researchers, e.g. Olins [40], suggest F-
actin involvement only in differentiation process.
Cytometric studies of F-actin level shows its decrease,
after the use of proapoptotic factor, in comparison to
control. Lower level of studied protein was also
observed by Shen et al. [32], after ATO application in
SHEE cells and by Veselska et al. [34], who used
ATRA in HL-60 cell line. The presence of F-actin in
the cytoplasm is indisputable, but there has been a dis-
pute for years, on this protein localization in nucleus.
F-actin presence in nuclei was described by Grzanka et
al. [33,39]. They suggested its role in chromatin reor-
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Fig. 5. Fluorescence microscopy studies of F-actin localization
changes in isolated nuclei after ATO treatment in K-562 cells. In
isolated nuclei from control cells F-actin was formed network
localized mainly in nucleus periphery. After ATO treatment F-actin
was formed granular structures. A – control (F-actin, DAPI); B –
0.6 µg/ml (F-actin, DAPI); C – 1.2 µg/ml (F-actin, DAPI).
Fig. 6. Flow cytometric cell cycle analysis
of K-562 cells after ATO treatment. Cells
were treated with ATO for 24h at concentra-
tions: 0.6, 1.2 and 2.4 µg/ml. Cell cycle
analysis showed the increase in percentage
of G1 and decrease in G2 phase cells.
ganization during the creation of morphological fea-
tures, characteristic for apoptotic cells. During the
present study it was revealed that the use of proapop-
totic factor caused chromatin condensation, thus F-
actin formed aggregated structures. Rapid changes,
taking place in the nucleus area and F-actin participa-
tion in the reorganization of chromatin, are probably
responsible for F-actin intensity level within this
organelle. It was pointed by Zhao et al. [2], that F-actin
is directly involved in chromatin reorganization, by
presence in BAF complex, where it acts as a
nucleotides shifting factor [2,41,42]. It was also told
that ANC-1 (domain, binding actin with the nucleus)
and UNC-84 protein are responsible of connecting
actin with nucleus [43]. Widlak et al. point actin influ-
ence on translocation of transcriptional RNA and in
determination of the chromosomal area, which limits
the mobility of chromatin fragments [42]. Other scien-
tists, like Hoffman et al., describe F-actin presence in
the process of retroviral RNA and protein kinase
inhibitor (PKI) transportation, due to nuclear actin
association with nucleoplasmatic filaments in nuclear
pore complex. Presented in present work, nuclear reor-
ganization of  F-actin under influence of ATO is prob-
ably connected with above-cited processes. Flow
cytometry, besides experiments pointing F-actin level
and cells percentage after ATO treatment, was also
used to study cell cycle. The use of ATO causes the
increased number of cells on G1 phase in compare to
control, and decreased in G2. Similar results were
obtained by Zhang et al. [45] who studied HL-60 and
Shao et al. [29] with human gastric carcinoma cells.
Other researchers, e.g. Liu [28] and Park [46] point
cells arrest in G2/M phase, after the use of ATO, how-
ever they emphasize that it depend on used cell line,
dose of cytostatic and time of incubation. Studies con-
ducted on seven myeloma cell lines indicate that it is
also dependent on whether the cell line is of wild type
or it has genes mutation, i.a. p35 or p21.
In conclusion, results, obtained in this work, indi-
cate on reorganization of F-actin, both cytoplasmic
and nuclear, after ATO treatment, in comparison to
control cells. ATO is also a proapoptotic factor and in
doses given in the article, it causes K-562 cells stop-
page in G1 phase of cell cycle.
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